Clinical Trials Logo

Advanced Solid Malignancies clinical trials

View clinical trials related to Advanced Solid Malignancies.

Filter by:

NCT ID: NCT01813474 Completed - Cancer Clinical Trials

Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies

Start date: March 25, 2013
Phase: Phase 1
Study type: Interventional

The objective of this study will be to investigate the safety and tolerability of olaparib tablet when given orally to Japanese patients with advanced solid malignancies. In addition, the pharmacokinetic profile, MTD (if possible) and efficacy of olaparib will be investigated.

NCT ID: NCT01800630 Completed - Clinical trials for Advanced Solid Malignancies

Phase1 Study of Gemcitabine HCl Oral Formulation(D07001-F4) in Patients With Advanced Solid Malignancies and Malignant Lymphomas

Start date: April 2013
Phase: Phase 1
Study type: Interventional

Open-label Phase 1 sequential dose-escalation study of 10 increasing doses (3 to 6 patients each)to determine and characterize the DLTs and MTD of gemcitabine HCl oral formulation (D07001-F4). Patients will be assigned to receive oral D07001-F4 on Days 1, 3, 5, 8, 10, and 12 of 4 21-day cycles each to further characterize safety and tolerability.

NCT ID: NCT01605916 Completed - Clinical trials for Non-Small Cell Lung Cancer

Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer

Start date: June 2012
Phase: Phase 1
Study type: Interventional

The objective of this study will be to investigate the safety and tolerability of AZD6244 given monotherapy or in combination with docetaxel as 2nd line therapy in Japanese patients with Advanced Solid Malignancies or Locally Advanced or Metastatic Non-Small Cell Lung Cancer. In addition, the pharmacokinetic profile of AZD6244 will be investigated. Following the combination regimen dose escalation phase (Part A) of the study additional patients may be enrolled to a dose expansion phase (Part B) to refine further the safety, tolerability, pharmacokinetics and biological activity of the combination in this patient population.

NCT ID: NCT01588548 Completed - Clinical trials for Advanced Solid Malignancies

Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma

Start date: July 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate the safety and tolerability of AZD 1208 up to a maximum tolerated dose (MTD) and define the dose(s) for further clinical evaluation when given daily to patients with advanced solid malignancies including malignant lymphoma

NCT ID: NCT01455584 Completed - Clinical trials for Advanced Solid Malignancies

Clinical Trial to Determine the MTD of HM781-36B in Patients With Advanced Solid Tumors

Start date: June 2011
Phase: Phase 1
Study type: Interventional

The main objective of this study is to determine the maximum tolerated dose (MTD) of HM781-36B continuously.

NCT ID: NCT01351350 Completed - Clinical trials for Hematologic Malignancies

Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies

Start date: February 28, 2011
Phase: Phase 1
Study type: Interventional

This is a Phase I, open label, dose escalation study of oral administration of MLN0128 in combination with paclitaxel, with/without trastuzumab, in participants with advanced solid malignancies.

NCT ID: NCT01340040 Completed - Cancer Clinical Trials

Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects

Start date: July 2011
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to explore the safety and tolerability of MEDI-573 in Japanese subjects with advanced solid tumours refractory to standard therapy or for which no standard therapy exists.

NCT ID: NCT01213160 Completed - Cancer Clinical Trials

Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient

Start date: November 2010
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to explore the safety and tolerability of AZD4547 in Japanese patients with advanced solid malignancies.

NCT ID: NCT01103791 Completed - Clinical trials for Advanced Solid Malignancies

A Trial to Determine the Maximum Tolerated Dose and Evaluate the Safety and Pharmacokinetics of Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel, in Subjects With Advanced Solid Malignancies

Start date: April 2010
Phase: Phase 1
Study type: Interventional

This is a phase I trial to determine the maximum tolerated dose and recommended phase II dose of docetaxel-PNP (polymeric nanoparticle formulation of docetaxel) and to evaluate the safety and pharmacokinetics of docetaxel-PNP in subjects with advanced solid malignancies.

NCT ID: NCT01102400 Completed - Clinical trials for Advanced Solid Malignancies

A Study of MEDI-575 in Patients With Advanced Solid Malignancies

Start date: March 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of MEDI-575 in Japanese patients with advanced solid tumors (dose escalation part) and hepatocellular carcinoma (expansion part).